As the largest animal vaccine company in China, Jinyu Bio-technology Co., Ltd. actively promotes the mission of Healthy China, and continuously improves its product quality by using global cutting-edge biotechnologies. With 60-year experience of animal vaccine R&D, manufacture and marketing, Jinyu has the most comprehensive portfolios in China covering pigs, cattle, sheep, poultry, waterfowl, pets etc.. By the end of 2016, Jinyu has become a dominant player in animal vaccine industry with revenue more than $ 200 million and market value of $ 3 billion.

The core competence of Jinyu is technological innovations. Jinyu first applies cell suspension culture, antigen concentration and purification process in veterinary vaccine production, which has upgraded the animal vaccine industry in China and improved product quality standards. To become a global player, Jinyu has built up an innovative, coordinated, ecological platform for the biomedical industry. Using internet of things and big data analysis, Jinyu aims to build a big data platform that offers data traceability and solutions for the prevention and control of animal diseases as well as food safety. With total investment of $ 700 million, Jinyu is building a world-class 45 hectares biopharmaceutical manufacturing and R&D platform which is completely driven by smart technology in line with Industry 4.0. For more information visit: www.jinyu.com.cn